We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for loncastuximab tesirine (Swedish Orphan Biovitrum Pty Ltd)
Active ingredients
loncastuximab tesirine
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Powder for concentrate for solution for infusion
Indication
Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
Therapeutic area
Oncology